Biocon gets observations from EDQM for API site in Bangalore

The company has announced that the European Directorate for the Quality of Medicines & HealthCare (EDQM) conducted a GMP inspection of an API manufacturing site of Biocon Limited in Bangalore from the 12th to 14th of September 2022 and issued a list of deficiencies on 5th October 2022. There were no critical deficiencies and one deficiency cited under the category 'Major'.

The company will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. Biocon remains committed to the Quality, Safety & Efficacy of its products.

Source : Equity Bulls

Keywords

Biocon EDQM GMPInspection APIManufacturingSite Bangalore Observations